| Project/Area Number |
16390414
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Sapporo Medical University |
|---|
Principal Investigator |
HONMOU Osamu Sapporo Medical University, School of Medicine, Assistant Professor (90285007)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
HOUKIN Kiyohiro Sapporo Medical University, School of Medicine, Professor (90229146)
HAMADA Hirofumi Sapporo Medical University, School of Medicine, Professor (00189614)
|
|---|
| Project Period (FY) |
2004 – 2007
|
| Project Status |
Completed (Fiscal Year 2007)
|
| Budget Amount *help |
¥15,250,000 (Direct Cost: ¥14,200,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2007: ¥4,550,000 (Direct Cost: ¥3,500,000、Indirect Cost: ¥1,050,000)
Fiscal Year 2006: ¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2005: ¥3,500,000 (Direct Cost: ¥3,500,000)
Fiscal Year 2004: ¥3,700,000 (Direct Cost: ¥3,700,000)
|
|---|
| Keywords | adult / gene / human / infarction / neural stem cell / stroke / transplantation / gene / human / infarction / neuroprotection / stroke / transplantation |
|---|
| Research Abstract |
Introduction : We have reported that transplantation of bone marrow cells has demonstrated therapeutic efficacy in animal models of cerebral ischemia. In the present study, we transplanted genetically-engineering bone marrow stem cells into middle cerebral artery occlusion model rats to study their potential therapeutic benefit.
Methdos : We have made five genetically-engineering bone marrow stem cells, 1) to immortalize the stem cells with hTERT gene, 2) to promote the neurotrophic effects with BDNF gene, 3) to promote the neurotrophic effects with GDNF gene, 4) to promote the angiogenetic effects with Ang-1 gene, 5) to promote the angiogenetic effects with P1GF gene. Lesion size was assessed using MR imaging and spectroscopy, and histological methods.
Results : Transplantation of genetically-engineering bone marrow stem cells reduced lesion volume. The reduction of lesion size could be assessed in vivo with MRI and was correlated with subsequent histological examination of the brain.
Conclusion : This work demonstrates that highly purified genetically-engineering bone marrow stem cells are neuroprotective and angeigenetic in cerebral ischemia models. Thus, a highly purified, expanded, and genetically-engineered cellular component of bone marrow has demonstrated the therapeutic benefits in cerebral ischemia.
|
